loading
Schlusskurs vom Vortag:
$1.63
Offen:
$1.53
24-Stunden-Volumen:
116.80K
Relative Volume:
0.47
Marktkapitalisierung:
$122.25M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-30.15M
KGV:
-1.3034
EPS:
-1.17
Netto-Cashflow:
$-31.63M
1W Leistung:
-19.74%
1M Leistung:
-25.97%
6M Leistung:
-24.88%
1J Leistung:
+88.27%
1-Tages-Spanne:
Value
$1.505
$1.5849
1-Wochen-Bereich:
Value
$1.505
$1.89
52-Wochen-Spanne:
Value
$0.77
$2.75

Context Therapeutics Inc Stock (CNTX) Company Profile

Name
Firmenname
Context Therapeutics Inc
Name
Telefon
267-225-7416
Name
Adresse
2001 MARKET STREET, PHILADELPHIA
Name
Mitarbeiter
9
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
CNTX's Discussions on Twitter

Vergleichen Sie CNTX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
CNTX 1.515 122.25M 0 -30.15M -31.63M -1.17
VRTX 449.25 115.43B 10.63B -479.80M -1.35B 13.33
REGN 748.22 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 588.46 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 247.73 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 106.50 24.89B 3.30B -501.07M 1.03B 11.54

Context Therapeutics Inc Aktie (CNTX) Neueste Nachrichten

pulisher
07:00 AM

Aclaris Therapeutics Secures Exclusive Licensing for Novel Antibody Therapies - MyChesCo

07:00 AM
pulisher
Nov 18, 2024

Tango Therapeutics director Mace Rothenberg acquires $74,000 in stock - Investing.com

Nov 18, 2024
pulisher
Nov 15, 2024

Avidity Partners Management LP Bolsters Stake in Context Therape - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

Blue Owl Capital Holdings LP Acquires Shares in Context Therapeu - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

GREAT POINT PARTNERS LLC Adjusts Stake in Context Therapeutics I - GuruFocus.com

Nov 15, 2024
pulisher
Nov 14, 2024

Driehaus Capital Management LLC Acquires Shares in Apogee Therap - GuruFocus.com

Nov 14, 2024
pulisher
Nov 11, 2024

Patient With Sickle Cell Disease Dies From Complications Related to Busulfan-Conditioning Following Treatment With Beam’s Base-Editing HSC Therapy BEAM-101 - CGTLive™

Nov 11, 2024
pulisher
Nov 11, 2024

Research Analysts Set Expectations for CNTX FY2024 Earnings - MarketBeat

Nov 11, 2024
pulisher
Nov 09, 2024

Circle S.p.A. Advances Digitalization in Logistics - MSN

Nov 09, 2024
pulisher
Nov 09, 2024

Context Therapeutics (NASDAQ:CNTX) Announces Earnings Results - MarketBeat

Nov 09, 2024
pulisher
Nov 09, 2024

Palvella Therapeutics Begins Phase 3 Trial for Microcystic Lymphatic Malformations Treatment - MyChesCo

Nov 09, 2024
pulisher
Nov 09, 2024

Annovis Bio Welcomes New Senior Clinical Scientist to Lead Key Studies - MyChesCo

Nov 09, 2024
pulisher
Nov 09, 2024

Redeemer Health Operating Deficit Surpasses $50 Million in Fiscal 2024 - MSN

Nov 09, 2024
pulisher
Nov 08, 2024

Context Therapeutics Announces Q3 2024 Financial Results and Strategic Advances - MyChesCo

Nov 08, 2024
pulisher
Nov 08, 2024

Keiretsu Forum Honors Top Innovators at Investor Capital Expo - MyChesCo

Nov 08, 2024
pulisher
Nov 07, 2024

3 Promising US Penny Stocks With At Least $90M Market Cap - Simply Wall St

Nov 07, 2024
pulisher
Nov 07, 2024

Century Therapeutics Expands Clinical Focus and Reports Steady Financials for Q3 2024 - MyChesCo

Nov 07, 2024
pulisher
Nov 07, 2024

BioAtla Reports Third Quarter 2024 Financial Results and Highlights Recent Progress - StockTitan

Nov 07, 2024
pulisher
Nov 07, 2024

Mineralys Therapeutics Set to Engage with Investors at Key Conferences - MyChesCo

Nov 07, 2024
pulisher
Nov 07, 2024

Viatris Inc. (NASDAQ:VTRS) Q3 2024 Earnings Call Transcript - MSN

Nov 07, 2024
pulisher
Nov 07, 2024

Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results - The Manila Times

Nov 07, 2024
pulisher
Nov 06, 2024

Hudson Bay Capital Management LP Acquires Shares in Context Ther - GuruFocus.com

Nov 06, 2024
pulisher
Nov 06, 2024

Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results - The Manila Times

Nov 06, 2024
pulisher
Nov 06, 2024

Alto Ingredients, Inc. Reports Third Quarter 2024 Results - The Manila Times

Nov 06, 2024
pulisher
Nov 06, 2024

Context Therapeutics Expands Pipeline Despite $17.5M Loss; $84.8M Cash Runway Into 2027 | CNTX Stock News - StockTitan

Nov 06, 2024
pulisher
Nov 06, 2024

Join Century Therapeutics at Guggenheim’s Healthcare Innovation Conference! - MyChesCo

Nov 06, 2024
pulisher
Nov 05, 2024

Stifel maintains $69 target on Beam Therapeutics stock - Investing.com

Nov 05, 2024
pulisher
Nov 05, 2024

Stifel maintains $69 target on Beam Therapeutics stock By Investing.com - Investing.com UK

Nov 05, 2024
pulisher
Nov 05, 2024

Protect Your Health: Discover the Life-Saving Potential of Early Lung Cancer Screenings at Local Hospitals - MyChesCo

Nov 05, 2024
pulisher
Nov 05, 2024

Carisma Therapeutics Welcomes Sohanya Cheng to Board of Directors - MyChesCo

Nov 05, 2024
pulisher
Nov 05, 2024

Is Weakness In Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects? - Yahoo Finance

Nov 05, 2024
pulisher
Nov 04, 2024

HR+ HER2-ve Breast Cancer Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail

Nov 04, 2024
pulisher
Nov 04, 2024

HR+ HER2-ve Breast Cancer Pipeline Therapeutics, Assessment, - openPR

Nov 04, 2024
pulisher
Nov 04, 2024

West Pharmaceutical Services Announces Upcoming Conference Presentations - MyChesCo

Nov 04, 2024
pulisher
Nov 01, 2024

Unpacking Q3 Earnings: Herbalife (NYSE:HLF) In The Context Of Other Consumer Staples Stocks - Yahoo Finance

Nov 01, 2024
pulisher
Oct 31, 2024

BioAtla to Announce Third Quarter 2024 Financial Results and Provide Business Highlights on November 7, 2024 - StockTitan

Oct 31, 2024
pulisher
Oct 28, 2024

Windtree Therapeutics announces $27.24 million equity sale option - Investing.com

Oct 28, 2024
pulisher
Oct 27, 2024

Spero Therapeutics, Inc. (NASDAQ:SPRO) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap? - Yahoo Finance

Oct 27, 2024
pulisher
Oct 26, 2024

Institutions along with retail investors who hold considerable shares inSeres Therapeutics, Inc. (NASDAQ:MCRB) come under pressure; lose 17% of holdings value - Simply Wall St

Oct 26, 2024
pulisher
Oct 25, 2024

Context Therapeutics to Engage Investors at November Conferences - MyChesCo

Oct 25, 2024
pulisher
Oct 23, 2024

Intensity Therapeutics grants stock options to top executives - Investing.com

Oct 23, 2024
pulisher
Oct 23, 2024

Context Therapeutics Inc (NASDAQ: CNTX) Gains 14.50% In Early Trade; What Lies Ahead? - Stocks Register

Oct 23, 2024
pulisher
Oct 23, 2024

Context Therapeutics to Participate in Upcoming Investor Conferences in November - GlobeNewswire

Oct 23, 2024
pulisher
Oct 22, 2024

Tolerance Bio Secures $17.2 Million to Advance Immune Disease Therapies - MyChesCo

Oct 22, 2024
pulisher
Oct 21, 2024

Er +/Her2 -Ve Breast Cancer Pipeline 2024: Clinical Trials - openPR

Oct 21, 2024
pulisher
Oct 18, 2024

National Secure Transport Expands Cash Services to Illinois with C3 Industries - MyChesCo

Oct 18, 2024
pulisher
Oct 17, 2024

Context Therapeutics to Showcase Promising Cancer Therapy at SITC Annual Meeting - MSN

Oct 17, 2024
pulisher
Oct 16, 2024

Alcura Secures MIA License to Enhance Cell and Gene Therapy Importation - MSN

Oct 16, 2024
pulisher
Oct 16, 2024

Context Therapeutics Announces Poster Presentation at the - GlobeNewswire

Oct 16, 2024
pulisher
Oct 16, 2024

Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting - StockTitan

Oct 16, 2024
pulisher
Oct 15, 2024

LVMH shows good resilience in the current context - Yahoo Finance

Oct 15, 2024

Finanzdaten der Context Therapeutics Inc-Aktie (CNTX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Kapitalisierung:     |  Volumen (24h):